Current Stem Cell Clinical Trials

UCLA

X-linked Chronic Granulomatous Disease
This study is a prospective non-controlled, non-randomized Phase I/II clinical trial to assess the safety, feasibility and efficacy of cellular gene therapy in patients with chronic granulomatous disease using transplantation of autologous bone marrow CD34+ cells transduced ex vivo by the G1XCGD lentiviral vector containing the human CGD gene.

Ages Eligible for Study: 23 Months and older
Genders Eligible for Study: Male

Contacts
Donald B Kohn, MD (310) 794-1964 dkohn1@mednet.ucla.edu
Caroline Kuo, MD (310) 825-6481 ckuo@mednet.ucla.edu


Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency
The study is open to twenty (20) infants and children diagnosed with ADA-deficient SCID who do not have a medically eligible, HLA-identical sibling donor for bone marrow transplantation.

Ages Eligible for Study: 1 Month and older
Genders Eligible for Study: Both

Contacts
Donald B Kohn, MD (310) 794-1964 dkohn1@mednet.ucla.edu
Kit L Shaw, PhD (310) 267-0584 kshaw@mednet.ucla.edu


Sickle Cell Disease
This Phase I clinical trial assesses the safety and initial evidence for efficacy of an autologous transplant of lentiviral vector modified bone marrow for adults with severe sickle cell disease.

Ages Eligible for Study: 18 Years and older
Genders Eligible for Study: Both

Contacts
Gary Schiller, MD 310-206-5755 gschiller@mednet.ucla.edu
Fabrizia Urbinati, PhD 310-794-1884 furbinati@ucla.edu


HIV
This Phase I clinical trial assesses the safety of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection. It is an early phase research study looking at whether an experimental gene transfer, LVsh5/C46 (also known as Cal-1), is safe and if it can protect the immune system from the effects of HIV without the use of antiretroviral drugs.

Ages Eligible for Study: 18 Years to 65 Years
Genders Eligible for Study: Both

Contacts
Maricela Gonzalez, 310-557-3729 mmgonzalez@mednet.ucla.edu
Principal Investigator: Ronald Mitsuyasu, M.D.


UC Irvine

A Phase I/II, Multi-Center, Open-Label Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Allogeneic Mesenchymal Bone Marrow Cells to Subjects with Ischemic Stroke, PI Steven C. Cramer, MD


A Double-Blind, Controlled Phase 2 Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients with Chronic Motor Deficit from Traumatic Brain Injury (TBI), PI Leonid Groysman, MD


A Double-Blind, Controlled Phase 2B Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients with Chronic Motor Deficit from Ischemic Stroke, PI Leonid Groysman, MD


A Phase IIA, Multi-Center, Randomized, Single-Blind, Placebo-Controlled, Crossover Study To Assess The Safety, Tolerability, And Preliminary Efficacy Of A Single Intravenous Dose of Allogeneic Human Mesenchymal Stem Cells To Subjects With Mild to Moderate Dementia Due to Alzheimer's Disease, PI Aimee Pierce MD


An Assessment of Humacyte's Human Acellular Vessel in Patients Needing Renal Replacement Therapy: A Comparison with ePTFE Grafts as Conduits for Hemodialysis (HUMANITY), PI Roy Fujitani, MD

 

Contact for all open studies at UCI is stemcell@uci.edu or 949-824-3990